European Growth Leverage the Immedica merger and existing Orion collaboration to accelerate ganaxolone market access in Europe, pursuing co-promotion, distribution partnerships, and regional licensing for CDKL5 deficiency disorder and other seizure indications.

Licensing Prospects With an exclusive Ovid patent license and Europe commercialization rights via Orion, Marinus is well positioned to pursue additional licensing deals or co-development partnerships for ganaxolone in other seizure disorders, expanding revenue opportunities.

Manufacturing Partnerships The company's size and manufacturing focus suggest opportunities to engage contract manufacturing and supply chain partners to scale ganaxolone production as commercial activity grows in the US and Europe, reducing time to market for new indications.

Financial Leverage Moderate revenue and available funding enable milestone-driven deals, upfronts, and royalties with partners, allowing flexible structuring to attract big pharma and specialty distributors while managing risk on key programs.

Risk-Aware Collaboration Ongoing litigation and fiduciary concerns imply a strong emphasis on governance and compliance; position Marinus as a partner that prioritizes rigorous due diligence and risk controls, which can appeal to risk-averse collaborators and large healthcare systems.